In today’s market, the demand for transparent product offerings with an unwavering focus on quality is increasingly sought after by industry brands but also by their customers. Suppliers of bioactive compounds and the quality they offer play a pivotal role in the overall success of launching a new product. When offering branded ingredients that align with the expectations of today’s conscious consumers, we are confident to say that when you choose MenaQ7®, you are in the best of hands.
Nature Identical K2 Crafted by Fermentation
Gnosis stands at the forefront of offering transparency with complete vertical integration in K2 development in scenic Italy. This unique position ensures 100% transparency, allowing full traceability and control throughout production. And you are welcome to have a closer look.
A 'Free-From' Portfolio for a Natural Ingredient
Brand owners incorporating MenaQ7® can formulate confidently, ensuring their product is free from allergens, like soy, and additives. Our K2 products, with their minimal ingredient list, are non-GMO, vegan-friendly, and hold certifications for being Kosher and Halal.
With MenaQ7®, our commitment to being the most clinically proven K2 as MK7 is unwavering. Backed by the attributes mentioned above, our dedication extends to the highest standard for Vitamin K2 quality, and we do not just promise it; we prove it.
Latest news & videos

- Corporate
- Digestion & Gut
- News
- Jun 06, 2025
Biotic Live: A Successful First Edition Exploring the Power of Probiotic Yeasts
Gnosis by Lesaffre recently hosted the first edition of Biotic Live, a unique event...

- Mobility & Joint
- MyCondro®
- News
- Jun 05, 2025
Redefining Joint Health: Gnosis by Lesaffre Showcases MyCondro™ at CMA Innovation Day
At the recent Innovation Day seminar hosted by Complementary Medicines Australia (CMA), Gnosis by...

- MenaQ7®
- Mobility & Joint
- News
- Jun 02, 2025
Supplementation with Menaquinone-7 (as MenaQ7®) Slows the Progression of Coronary Artery Calcification
The first results from the VitaK-CAC Trial, “Menaquinone-7 Slows Down Progression of Coronary Artery...